BCL2 apoptosis regulator
B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein and the founding member of the Bcl-2 family, a group of structurally related regulators of programmed cell death.
B-cell lymphoma 2 (Bcl-2) is an anti-apoptotic protein and the founding member of the Bcl-2 family, a group of structurally related regulators of programmed cell death. It is an integral membrane protein localized primarily to the outer mitochondrial membrane, with additional pools at the endoplasmic reticulum and nuclear envelope, and it governs the intrinsic (mitochondrial) pathway of apoptosis. Bcl-2 acts by binding and neutralizing pro-apoptotic family members through its hydrophobic BH3-binding groove, thereby preventing permeabilization of the outer mitochondrial membrane, blocking cytochrome c release, and suppressing downstream activation of the caspase cascade, including Caspase-3 (CASP3) and the cleavage of Poly(ADP-ribose) polymerase 1 (PARP1). Because these cleavage events are hallmarks of apoptotic commitment, Bcl-2 levels — often assessed relative to pro-apoptotic counterparts — are widely used as a readout of a cell's survival threshold under stressors such as reactive oxygen species, DNA damage, growth factor withdrawal, and disrupted calcium handling.
Bcl-2 sits downstream of several major survival signaling axes, including the phosphatidylinositol 3-kinase (Phosphatidylinositol 3-kinase (PI3K))/protein kinase B (PKB)/Mechanistic target of rapamycin (Mtor) pathway, JAK2/STAT3 signaling, and NF-κB, and its expression is shaped by transcriptional regulators such as TP53, MYC proto-oncogene (MYC), and Forkhead box O1 (FOXO1). Beyond apoptosis, Bcl-2 restrains autophagy by sequestering Beclin-1, linking it to lysosomal and autophagic stress responses. Pathologically, Bcl-2 overexpression — classically driven by the t(14;18) translocation in follicular lymphoma, and observed in chronic lymphocytic leukemia, acute myeloid leukemia, and many solid tumors — sustains malignant cell survival and contributes to resistance against chemotherapy and radiotherapy. This made Bcl-2 a prototypical target for BH3-mimetic drugs, of which venetoclax (ABT-199) is the clinically established selective inhibitor; its activity is frequently limited by compensatory reliance on the related survival protein Myeloid cell leukemia 1 (MCL1), motivating combinations with agents targeting parallel pathways. Bcl-2 is likewise a common mechanistic endpoint in preclinical studies of natural products, kinase inhibitors, and physical therapies such as photodynamic treatment, where altered Bcl-2 expression is used to demonstrate engagement of apoptotic signaling in both cancer and non-malignant tissue injury models.
Where the papers sit
28 papers from the last 6 months study BCL2 apoptosis regulator directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 2 observational · 6 human data · 16 preclinical · 4 unclassified
Themes 4 themes
-
BCL2-Linked Mitochondrial Signaling
Small molecules, natural extracts, peptides, RNAi constructs, and AI-guided repurposing are expanding ways to disrupt BCL2-linked survival in cancer. Mitochondrial apoptosis, ROS, mitophagy, cell-cycle arrest, and impaired migration recur across breast and colorectal models, with occasional extension to melanoma. Engineered dual RNAi and structure-guided peptides point toward more selective multi-pathway targeting than nonspecific cytotoxicity. Evidence is predominantly in vitro or computational, leaving delivery, selectivity, and clinical efficacy open.
12 papers · 42.9%
-
BCL2-Targeted Blood Cancers
Venetoclax is moving from established mantle cell lymphoma use toward combination and outcome-guided treatment in AML and aggressive B-cell lymphoma. PI3Kδ inhibition with YY-20394 plus ABT199 shows a combination strategy, while febrile neutropenia highlights treatment toxicity. Hi-C and molecular profiling recur as tools for detecting rearrangements and explaining relapse. Evidence remains largely retrospective or preclinical, with durable benefit and resistance still open.
8 papers · 28.6%
-
Experimental Apoptosis Modulation
Natural products, photodynamic therapy, and synthetic compounds are being screened for apoptosis-inducing activity across neurological, reproductive, and cancer models. BAX/BCL2 balance, caspase-3 activation, calcium or oxidative stress, and Annexin V/flow cytometry recur as readouts. Some interventions aim to protect normal tissue while killing resistant tumor cells. The work remains mechanistic and preclinical, without a common therapeutic lead.
5 papers · 17.9%
-
Liver Disease Target Discovery
Combination treatment is favored over sorafenib alone in liver cancer, with clomipramine proposed to overcome lysosomal sequestration and autophagy-linked resistance. Network pharmacology and docking broaden the search toward nutraceutical targets, while gut microbiota metabolites connect immune regulation to high-risk primary biliary cholangitis. Macrophages and autophagy recur as candidate mechanisms rather than validated clinical targets. The field is still generating hypotheses, and causal benefit in patients remains unresolved.
3 papers · 10.7%
Papers
The 28 papers from the last 6 months that study BCL2 apoptosis regulator directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
BCL2-Linked Mitochondrial Signaling (12)
- Engineered dual RNAi prodrug for combined suppression of survival and cell cycle pathways in triple negative breast cancer treatment. Chemical communications (Cambridge, England) · 16 Oct 2026 PMID 42885730
- Rational structure-guided identification of a Bcl-2-targeting peptide with antiproliferative effects on colorectal cancer cells. Journal of enzyme inhibition and medicinal chemistry · 15 Oct 2026 PMID 42875898
- Tibetan medicine Anzhi Jinghua San alleviates chronic atrophic gastritis: attenuation of LysoPC-induced Bcl-2 suppression and inhibition of pyroptosis and apoptosis. Journal of ethnopharmacology · 13 Oct 2026 PMID 42869398
- Targeting BCL-2 through Deep Learning-Based Drug Repurposing: A Multimodal Approach Combining Diffusion-Based Generative Modeling, Neural Relational Inference, and In Vitro Validation. Journal of chemical information and modeling · 14 Sept 2026 PMID 42734502
- CRC cell cycle arrest and early apoptosis induction by mononuclear octahedral cobalt(III) Schiff base through the inhibition of CDK4/6 and BCL2. Medical oncology (Northwood, London, England) · 5 Sept 2026 PMID 42700291
- Berberine Modulates Mitophagy-Related Gene Expression and Suppresses Breast Cancer Cells: A Multi-Omics and Experimental Study. Cell biochemistry and biophysics · 26 Aug 2026 PMID 42645668
- A pilot single-case longitudinal multi-omics of canine oral melanoma characterizes endogenous mutation patterns and radiotherapy-associated responses. Gene · 24 Jun 2026 PMID 42342053
- Discovery of new thiazolyl hydrazone derivatives as anti-breast cancer agents: Synthesis, biological evaluation and in silico studies. Bioorganic chemistry · 19 Jun 2026 PMID 42320114
- Reverse engineering of BNIP3 identifies a mitochondrial protective peptide. Nature communications · 17 Jun 2026 PMID 42309990
- Bisphenol A exacerbates diabetic foot ulcers through disruption of immune microenvironment and repair processes: a multi-omics analysis of environmental exposure mechanisms. Drug and chemical toxicology · 15 Jun 2026 PMID 42298305
- Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. Renal failure · 31 May 2026 PMID 42219284
- Ethanolic extract of Otostegia fruticosa induces ROS-dependent apoptosis and reduces migration of MDA-MB-231 cells in vitro. PloS one · 26 May 2026 PMID 42189838
BCL2-Targeted Blood Cancers (8)
- Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma. Molecular biology reports · 7 Sept 2026 PMID 42704540
- Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis. European journal of clinical pharmacology · 1 Aug 2026 PMID 42541584
- Mechanistic study on the treatment of androgenetic alopecia with Platycladus orientalis leaf extract via regulation of the VEGFA/Bcl2 pathway: An in silico and in vitro study. Medicine · 18 Jul 2026 PMID 42469978
- Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma. Blood advances · 10 Jul 2026 PMID 42431614
- PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells. Oncology reports · 19 Jun 2026 PMID 42318952
- Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. Blood advances · 17 Jun 2026 PMID 42308239
- Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
- First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma. Cancer discovery · 21 May 2026 PMID 42166034
Experimental Apoptosis Modulation (5)
- Anticancer activity of asiatic acid in cisplatin-resistant human neuroblastoma SH-SY5Y and its unaffected effect on human neural stem cells. PloS one · 15 Sept 2026 PMID 42743141
- Effects of interstitial photodynamic therapy on transplanted tumors of human lung adenocarcinoma A549 cells in nude mice. Lasers in medical science · 10 Jul 2026 PMID 42429993
- Resveratrol Ameliorates PTZ-Induced Seizure Activity and Diaphragm Muscle Dysfunction by Regulating Calcium Handling and Apoptotic Pathways in Rats. Molecular neurobiology · 9 Jul 2026 PMID 42426356
- Protective effects of Withania somnifera (Ashwagandha) against chronic unpredictable mild stress-induced testicular damage in adolescent rats. Journal of molecular histology · 18 Jun 2026 PMID 42315798
- Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways. Journal of medicinal chemistry · 11 Jun 2026 PMID 42273719
Liver Disease Target Discovery (3)
- Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PloS one · 13 Aug 2026 PMID 42594087
- A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. PloS one · 1 Jul 2026 PMID 42384725
- Clomipramine potentiates sorafenib efficacy in experimental hepatocellular carcinoma by targeting lysosomal sequestration and modulating the cathepsin B/Bcl-2/Beclin-1 axis. Molecular biology reports · 30 Jun 2026 PMID 42377685
By study type
Observational studies and case reports (2)
- Association between venetoclax concentration and febrile neutropenia in acute leukemia: a retrospective analysis. European journal of clinical pharmacology · 1 Aug 2026 PMID 42541584
- Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
Human data, design not indexed (6)
- Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma. Molecular biology reports · 7 Sept 2026 PMID 42704540
- CRC cell cycle arrest and early apoptosis induction by mononuclear octahedral cobalt(III) Schiff base through the inhibition of CDK4/6 and BCL2. Medical oncology (Northwood, London, England) · 5 Sept 2026 PMID 42700291
- Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PloS one · 13 Aug 2026 PMID 42594087
- Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma. Blood advances · 10 Jul 2026 PMID 42431614
- Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. Blood advances · 17 Jun 2026 PMID 42308239
- First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma. Cancer discovery · 21 May 2026 PMID 42166034
Preclinical: animal, cell and lab studies (16)
- Engineered dual RNAi prodrug for combined suppression of survival and cell cycle pathways in triple negative breast cancer treatment. Chemical communications (Cambridge, England) · 16 Oct 2026 PMID 42885730
- Rational structure-guided identification of a Bcl-2-targeting peptide with antiproliferative effects on colorectal cancer cells. Journal of enzyme inhibition and medicinal chemistry · 15 Oct 2026 PMID 42875898
- Anticancer activity of asiatic acid in cisplatin-resistant human neuroblastoma SH-SY5Y and its unaffected effect on human neural stem cells. PloS one · 15 Sept 2026 PMID 42743141
- Targeting BCL-2 through Deep Learning-Based Drug Repurposing: A Multimodal Approach Combining Diffusion-Based Generative Modeling, Neural Relational Inference, and In Vitro Validation. Journal of chemical information and modeling · 14 Sept 2026 PMID 42734502
- Mechanistic study on the treatment of androgenetic alopecia with Platycladus orientalis leaf extract via regulation of the VEGFA/Bcl2 pathway: An in silico and in vitro study. Medicine · 18 Jul 2026 PMID 42469978
- Effects of interstitial photodynamic therapy on transplanted tumors of human lung adenocarcinoma A549 cells in nude mice. Lasers in medical science · 10 Jul 2026 PMID 42429993
- Resveratrol Ameliorates PTZ-Induced Seizure Activity and Diaphragm Muscle Dysfunction by Regulating Calcium Handling and Apoptotic Pathways in Rats. Molecular neurobiology · 9 Jul 2026 PMID 42426356
- A network pharmacology-based approach and molecular docking study to explore the therapeutic potential of a nutraceutical formula (Vernolac) in the treatment of cancer. PloS one · 1 Jul 2026 PMID 42384725
- Clomipramine potentiates sorafenib efficacy in experimental hepatocellular carcinoma by targeting lysosomal sequestration and modulating the cathepsin B/Bcl-2/Beclin-1 axis. Molecular biology reports · 30 Jun 2026 PMID 42377685
- Discovery of new thiazolyl hydrazone derivatives as anti-breast cancer agents: Synthesis, biological evaluation and in silico studies. Bioorganic chemistry · 19 Jun 2026 PMID 42320114
- PI3Kδ inhibitor YY‑20394 is effective alone or in combination with Bcl‑2 inhibitor ABT199 in acute myeloid leukemia cells. Oncology reports · 19 Jun 2026 PMID 42318952
- Protective effects of Withania somnifera (Ashwagandha) against chronic unpredictable mild stress-induced testicular damage in adolescent rats. Journal of molecular histology · 18 Jun 2026 PMID 42315798
- Reverse engineering of BNIP3 identifies a mitochondrial protective peptide. Nature communications · 17 Jun 2026 PMID 42309990
- Design, Synthesis, and Evaluation of Antitumor Activity of Novel Phenylahistin Derivatives with Double F-Substitution via Dual Inhibition of Microtubule and P53/BCL-2/BAX Signaling Pathways. Journal of medicinal chemistry · 11 Jun 2026 PMID 42273719
- Combining bioinformatics and machine learning to analyze and validate sepsis-related cell senescence genes and potential drugs. Renal failure · 31 May 2026 PMID 42219284
- Ethanolic extract of Otostegia fruticosa induces ROS-dependent apoptosis and reduces migration of MDA-MB-231 cells in vitro. PloS one · 26 May 2026 PMID 42189838
Unclassified: not yet indexed with MeSH (4)
- Tibetan medicine Anzhi Jinghua San alleviates chronic atrophic gastritis: attenuation of LysoPC-induced Bcl-2 suppression and inhibition of pyroptosis and apoptosis. Journal of ethnopharmacology · 13 Oct 2026 PMID 42869398
- Berberine Modulates Mitophagy-Related Gene Expression and Suppresses Breast Cancer Cells: A Multi-Omics and Experimental Study. Cell biochemistry and biophysics · 26 Aug 2026 PMID 42645668
- A pilot single-case longitudinal multi-omics of canine oral melanoma characterizes endogenous mutation patterns and radiotherapy-associated responses. Gene · 24 Jun 2026 PMID 42342053
- Bisphenol A exacerbates diabetic foot ulcers through disruption of immune microenvironment and repair processes: a multi-omics analysis of environmental exposure mechanisms. Drug and chemical toxicology · 15 Jun 2026 PMID 42298305
Written from 28 PubMed abstracts, each one listed by PMID above. Published: 2026-06-17. Last written: 2026-09-16 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.